Taiwan IPC Weekly News 15 May, 2025

A Medicine Development Company, Energenesis Biomedical, Makes Its First Debut at COMPUTEX, Showcasing AI-Driven Drug Discovery Achievements

Source: 華安COMPUTEX首次參展 秀AI新藥研發成果

Original News Issued Date: 14 May 2025

What to learn from this article:

• "Energenesis, a drug development company, makes its debut at the prestigious COMPUTEX event, showcasing its AI-driven advancements in medicine."
• "Energenesis effectively integrates AI technology into its drug development process, utilizing proprietary platforms and advanced AI tools to identify new indications for existing drugs."
• "Through strategic partnerships, Energenesis collaborates to expand its AI capabilities and accelerate the development and commercialization of new medicines."

Energenesis Biomedical Co., Ltd., a drug development company, announced its debut participation in COMPUTEX 2025, one of the world’s premier annual technology events, taking place from May 20 to 23. The company will exhibit its AI-powered drug discovery achievements in the InnoVEX startup section, in alignment with this year’s theme, “AI NEXT.”

General Manager Dr. Han-Min Chen noted that Energenesis has developed a proprietary AI drug repositioning platform, which has already identified several promising candidates for further development. The company plans to begin research validation this year and file for patents related to its AI-identified compounds. These efforts aim to establish a new business licensing model and mark a significant step toward the company’s next phase of growth.

Dr. Chen emphasized that as the AI-driven transformation of the industry gains momentum, Energenesis has positioned itself as one of Taiwan’s leading pioneers in AI-powered drug repositioning. The company has already achieved early results in addressing unmet medical needs, particularly in areas such as rare diseases and infectious diseases. Looking ahead, Energenesis is open to forming strategic partnerships to further expand its AI capabilities and accelerate both drug development and commercialization.

Energenesis Biomedical is a medicine development company that utilizes its proprietary ‘ENERGI’ drug development platform to target indications such as diabetic foot ulcers (F703DFU), alopecia areata (F701), venous leg ulcers (F703VLU), epidermolysis bullosa (F703EB), and Parkinson’s disease (F705PD).

InnoVEX is widely recognized as a premier global platform for startup matchmaking and a key venue for Taiwanese startups to connect with the international market. This year’s event is expected to bring together over 450 technology and startup companies from more than 24 countries and regions, alongside more than 30 themed pavilions. Notably, Energenesis will be the only Taiwan-based drug development company participating in InnoVEX.

Energenesis’s AI initiatives are supported by strategic partnerships with industry leaders including AI chipmaker NVIDIA, SSD manufacturer Phison Electronics, the Industrial Technology Research Institute (ITRI), and National Yang Ming Chiao Tung University (NYCU). At COMPUTEX, the company will highlight its use of NVIDIA’s AI tools designed for drug discovery, including the ‘Clara’ toolkit, the generative AI cloud platform ‘BioNeMo’, and the H200 platform. Energenesis will also showcase its integration of Phison’s newly launched ‘aiDAPTIV+’ service, which enables large-scale AI model training. In collaboration with NYCU, the company is leveraging the ‘Llama 3’ AI model to analyze vast datasets of biological information and scientific literature—yielding promising early results in identifying new indications for existing drugs. These efforts underscore Energenesis’s comprehensive approach to integrating AI into the drug development process.

To strengthen its AI capabilities, Energenesis has not only built a dedicated team of AI specialists but also plans to establish on-premises AI training models to safeguard data integrity and boost overall competitiveness. The company’s AI system is being trained to screen over 1,700 FDA-approved small-molecule drugs, with the goal of identifying potential new indications from these compounds. When the AI model identifies a promising candidate, the team will proceed with validation through cell and animal studies. If the results are positive, Energenesis will file for relevant drug patents and begin licensing negotiations.

Acqutek specializes in supporting our customers with industrial-grade computers from Taiwanese manufacturers.

 --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Acqutek specializes in supporting our customers with industrial-grade computers from Taiwanese manufacturers.